

Pre-Program Activities	Pre-Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Pre-Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
7:30 am	<i>Registration and View Exhibits</i>
8:00 am	Opening Comments and Pre-Test
8:20 am	Advances in the Screening and Treatment of HCV <ul style="list-style-type: none"> • Highlight of Pre-Lecture 1 • Updates on diagnostic approaches • Screening and Treatment of HCV • Caring for At-risk populations – homeless, PWID, the incarcerated • Novel FDA Approved Direct Acting Anti-virals • Clinical Cases and Discussion
9:10 am	Hepatitis B: Epidemiology, Natural History, Testing and Treatment <ul style="list-style-type: none"> • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • Disease progression and impact on liver health • The efficacy of HBV Vaccination • Anti-viral therapies of HBV • The growing relationship between HBV and HDV • HBV Re-activation • Latest studies from EASL and AASLD
9:40 am	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> • Global and US perspective on the growth of Delta Hepatitis • Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards • Testing and surveillance approaches • Real world outcome studies on HDV and HEV • Management of Chronic HEV
10:15 am	<i>Break and View exhibits</i>
10:30 am	End Stage Liver Disease: Recap and Clinical Cases <ul style="list-style-type: none"> • A review of Pre-course lecture on end-stage liver disease • Complications of cirrhosis • Liver transplant in the era of DAA's • Clinical cases to illustrate HE, HRS and/or Thrombocytopenia
11:05 am	Hepatocellular Carcinoma(HCC) - Screening and Disease Progression <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Treatment and management options: Ablation, TACE and Surgery • New studies showing cost effectiveness of surveillance post SVR • PRIUS Study (MRI vs US) Abbreviated MRI • 2023 AASLD screening guidance for liver cancer • AASLD guidance is less critical of liver biopsy for cancer detection
11:40 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • A case-based approach to HCC treatment • Promising 1st and 2nd line therapies for liver cancer • New data on the benefit of downstaging • New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC • Checkpoint inhibitors and VEGE inhibitors
12:20 pm	<i>Luncheon and Product Information Session</i>
12:55 pm	<i>Dessert and View Exhibits</i>

1:05 pm	<p>Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis</p> <ul style="list-style-type: none"> • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival in PSC patients • Causes and Markers of PBC • Coping with the clinical features of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid • Highlights of the ELATIVE study on elafibranor and the ENHANCE study on seladelpar
1:55 pm	<p>Alcohol Associated Liver Disease</p> <ul style="list-style-type: none"> • The growing prevalence of alcohol over-consumption and its impact on liver health • Alcohol consumption and malnutrition • Warning signs and intervention in alcohol-associated hepatitis • Promising therapeutic agents for AAH
2:30 pm	<p><i>Break & View Exhibits</i></p>
2:45 pm	<p>Steatotic Liver Disease: The new healthcare epidemic</p> <ul style="list-style-type: none"> • New naming conventions for fatty liver disease: MASLD and MASH– what and why? • Epidemiology, Demographics and Diagnosis • Scoring, Staging and Management of Metabolic Liver Disease • The ‘unhealthy’ rise in MASLD in the US population and What can be done • Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:20 pm	<p>MASH Treatments in Practice and in Development</p> <ul style="list-style-type: none"> • Current therapies for NASH including Updates from AASLD and EASL • Lifestyle changes as a therapy • Drugs in clinical development for NASH – Semaglutide and Resmitemon • MASH Diagnosis and Treatment case
4:00 pm	<p>Closing Comments, Post-test and Wrap-Up Program adjourns at 4:15 pm</p>
Post-program activities	<p>Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome 30 minutes</p> <p>Lecture 4 - Overcoming barriers to liver health in special populations - 45 minutes</p> <p>Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting – 30 min</p>

Course Director: Paul J. Pockros, MD - Scripps Health

Peer Review: Tracy Ander, DO - University of Louisville School of Medicine